Joanne P. LaGanke MS Center

North Central Neurology Associates, P.C.

Click here to edit subtitle


PASSAGE

Novartis: Long-term, prospective, observational, multinational, parallel-cohort study monitoring the safety in patients with MS, newly started with XXX once daily or treated with another approved disease-modifying therapy. Open to enrollment, contact Mitzi for more information.



TERIKIDS

Genzyme, A Sanofi Company: A two year, multi-center, randomized, double-blind, placebo-controlled, parallel group trial to evaluate efficacy, safety, tolerability, and pharmacokinetics of XXXX administered orally once daily in pediatric patients with relapsing forms of multiple sclerosis. Open to enrollment, contact Gena for more information.



EVOLVE

Alkermes: A Phase 3 Study in Subjects with Relapsing Remitting Multiple Sclerosis to Evaluate the Tolerability of XXXX and XXXX. Open to enrollment, contact Amanda for more information.



ASCLEPIOS

Novartis: A Randomized, Double-Blind, Double Dummy, Parallel-Group Study Comparing the Efficacy and Safety of XXXX versus XXXX in Patients with Relapsing Multiple Sclerosis. Open to enrollment, contact Gena for more information.



LILAC

Pfizer: A Randomized, Double-Blind, Placebo Controlled, Parallel Group, Multi-Center Trial of XXXX As Adjunctive Therapy in Pediatric and Adult Subjects with Primary Generalized Tonic-Clonic Seizures. Open to enrollment, contact Mitzi or Angie for more information.


PRO-ACT

Genzyme, A Sanofi Company: A Prospective, 24-Month Observational Study to Evaluate Patient Reported Outcomes and Safety After LEMTRADA Treatment in Patients With Relapsing Multiple Sclerosis Switching From A Prior Disease Modifying Therapy. Open to enrollment, contact Mitzi.


PASS

Genzyme, A Sanofi Company: A Prospective, Multicenter Observational, Post-Authorization Safety Study to Evaluate the Long Term Safety Profile of LEMTRADA (alemtuzumab) Treatment in Patients With Relapsing Forms of Multiple Sclerosis. Open to enrollment,  contact Angie for more information.


LEM-COG

Genzyme, A Sanofi Company: A Prospective 24-Month Observational Study to Evaluate Neurocognitive Function and Safety in Patients with Relapsing Multiple Sclerosis Who Are Initiating LEMTRADA Treatment in Routine Clinical Practice. Open to enrollment, contact Amanda for more information.


VELOCE

Roche: A Phase IIIB, Multicenter, Randomized, Parallel-Group, Open-Label Study To Evaluate the Effects of XXXX on Immune Responses With Relapsing Forms of Multiple Sclerosis. Closed to enrollment.


CHORDS

Genentech: An Open-Label Study To Evaluate The Effectiveness And Safety Of XXXX in Patients With Relapsing Remitting Multiple Sclerosis Who Have Had A Suboptimal Response To An Adequate Course Of Disease-Modifying Treatment. Closed to enrollment.